MATN Mateon Therapeutics Inc.

MATEON TO PARTICIPATE IN MERIDIAN CLINICAL TRIALS SUMMIT

MATEON TO PARTICIPATE IN MERIDIAN CLINICAL TRIALS SUMMIT
EN
14/10/2020

Underlying

MATNMateon Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Mateon Therapeutics Inc.

 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic Therapeutics Showcases Robust Pipeline and Founder’s Broad I...

Oncotelic Therapeutics Showcases Robust Pipeline and Founder’s Broad Intellectual Property Contributions to Biopharma Industry Highlighting multibillion-dollar drug discoveries and advancing novel oncology and immunotherapy assets AGOURA HILLS, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“OTLC” or the “Company”), a clinical stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, today highlights the depth of its oncology and immunotherapy pipeline while recognizing the extraordinary intellectual property c...

August 28, 2025 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic Therapeutics Highlights Peer‑Reviewed Publication Linking TG...

Oncotelic Therapeutics Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients Data support further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma (PDAC). AGOURA HILLS, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical‑stage biopharmaceutical company developing RNA‑targeted and small‑molecule therapeutics for cancer and rare diseases, today highlighted the publication of new translational ...

July 17, 2025 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB...

Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer AGOURA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on RNA-based therapeutics, today announced the publication of a peer-reviewed research article highlighting TGFB2 gene methylation as a positive prognostic biomarker for pancreatic ductal adenocarcinoma (PDAC). The paper, published in collaboration with Sapu Biosciences,...

June 25, 2025 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platfo...

Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm AGOURA HILLS, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC), a biotechnology company focused on nanomedicine and RNA-based therapeutics, announced today that its Chairman and CEO, Dr. Vuong Trieu, will deliver a keynote presentation at the 21st Annual Congress of International Drug Discovery Science & Technology (IDDST-Europe), scheduled for June 18-20, 2025, in Stockholm, Sweden. Dr. Trieu's presentation, titled " Deciparticles: Nov...

April 22, 2025 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings...

Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023  AGOURA HILLS, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, pancreatic ductal adenocarcinoma (“PDAC”), diffuse intrinsic pontine glioma (“DIPG”), and various other cancers, today announced its financial results for the fiscal year ended December 31, 2024 (“FY 2024”), as compared to the fiscal year ended December 31, 2023 (“FY 2023”). T...

April 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch